Drug Trial Radar · NCT05037409
Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants
Last checked: Nov 20, 2026Latest source record: Dec 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Sep 28, 2021
Primary completion
Mar 27, 2022
Study completion Mar 27, 2022
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Purpose of the study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics (PK) of PF-06823859 following a single intravenous dose of PF-06823859 300 and 900 mg in Japanese healthy adult participants.
Conditions
- Healthy
Interventions
PF-06823859Drug
low dose or high dose intravenous infusion
PlaceboDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to maximum of Day 157
- Number of Participants With Infusion Related Reaction (IRR)Time frame: Day 1 up to maximum of Day 157
- Number of Participants With Infusion Site ReactionTime frame: From start of study intervention infusion up to 60 minutes on Day 1
- Number of Participants With Viral InfectionTime frame: Day 1 up to maximum of Day 157
- Number of Participants With Laboratory Test AbnormalitiesTime frame: Day 1 up to maximum of Day 157
- Number of Participants With Vital Sign Abnormalities of Pre-defined CriteriaTime frame: From baseline (pre-dose measurement at Day 1) up to Day 157
- Number of Participants With Electrocardiogram (ECG) Abnormalities of Pre-defined CriteriaTime frame: From baseline (pre-dose measurement at Day 1) up to Day 157
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical Corporation Shinanokai Shinanozaka Clinic
Shinjuku-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.